Human embryonic stem cell therapy for Parkinson's disease

Author: Ben-Hur, Tamir

Source: Future Neurology, Volume 1, Number 2, March 2006 , pp. 227-236(10)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Human embryonic stem cells (hESCs) may serve as the most enduring source of transplantable cells for Parkinson's disease patients. Accumulating experience in the transplantation of fetal midbrain tissue or cells into Parkinson's disease patients has set the stage for hESC therapy, but has also opened new controversies on the value and appropriate design of cell therapy. hESCs can be directed to differentiate into nigral dopaminergic neurons with high efficiency. The clinical use of hESCs will depend on their growth in controlled conditions, on whether safety can be proven, and on improving the survival of hESC-derived dopaminergic neurons in the host brain.

Keywords: dopamine neuron; human embryonic stem cells; Parkinson's disease; transplantation

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14796708.1.2.227

Publication date: 2006-03-01

More about this publication?

Future Neurology provides a forum to address the most important challenges and advances in our understanding of neurological disease, and highlights emerging trends and prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson's disease.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites